Obiekt

Tytuł: Quantitative PCR (RQ-PCR) in monitoring of minimal residual disease in Chronic Myeloid Leukemia patients

Abstrakt:

Philadelphia chromosome (Ph) - the characteristic chromosomal abnormality in hematopoietic stem cells causes chronic myeloid leukemia (CML). It develops during reciprocal translocation between long arms chromosomes 9 and 22. The translocation results in a fusion gene BCR-ABL which is responsible for synthesis of a constitutively activated tyrosine kinase. Cells carrying the translocations can be identified by several methods: cytogenetic analysis, FISH (Fluorescence In situ Hybridization) and RT-PCR (Reverse Transcriptase Polymerase Chain Reaction). One of the molecular methods uses to CML diagnostics there is also RQ-PCR (Real-time Quantitative PCR). It allows estimating very accurately the expression of the genes and application of molecular probe causes this method very specific and sensitive. Thanks to this technique there is the possibility to monitoring the therapy advance and minimal residual disease in CML patients. Up regulation of BCR-ABL gene, helps to detect the relapse even a few months before clinical signs of leukemia and modification of treatment. 60 patients with CML were qualified to the study group. All of them were cured in Hematology Department CMUJ in Krakow. Expression of BCR-ABL gene was measured for about three months. RQ-PCR method was performed by ABIPRISM 7700 using TaqMan technology. As a positive control uses to generate the standard curve plasmid ; dilutions were used. Differences between transcripts level during therapy were presented as a ratio of BCR-ABL to ABL copy number, and correlates to clinical image of the patients. The sensitivities of the tests were oscillated about 104 – 105. RQ-PCR method is very efficient and accurate assay to monitor BCR-ABL expression in CML patients treated with Imatinib and another tyrosine kinase inhibitors. RQ-PCR is reliable and sensitive method for monitoring CML patients after therapy. This is also convenient, robust and routine method for monitoring of minimal residual disease in CML patients. Quantifications of the level of residual disease using RQ-PCR has also therapeutic implications for the follow-up of therapeutic interventions for relapse.

Miejsce wydania:

Kraków

Stopień studiów:

2 - studia doktoranckie

Dyscyplina:

onkologia

Instytucja nadająca tytuł:

Wydział Lekarski

Promotor:

Skotnicki, Aleksander

Data wydania:

2007

Identyfikator:

oai:dl.cm-uj.krakow.pl:973

Sygnatura:

ZB-107305

Język:

pol

Prawa dostępu:

nieograniczony

Kolekcje, do których przypisany jest obiekt:

Data ostatniej modyfikacji:

26 cze 2023

Data dodania obiektu:

21 lis 2012

Liczba wyświetleń treści obiektu:

1 498

Liczba wyświetleń treści obiektu w formacie PDF

240

Wszystkie dostępne wersje tego obiektu:

http://dl.cm-uj.krakow.pl:8080/publication/973

Wyświetl opis w formacie RDF:

RDF

Wyświetl opis w formacie OAI-PMH:

OAI-PMH

Nazwa wydania Data
ZB-107305 26 cze 2023
×

Cytowanie

Styl cytowania:

Ta strona wykorzystuje pliki 'cookies'. Więcej informacji